Morphic Holding, Inc. (NASDAQ:MORF) Stock Holdings Increased by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. lifted its stake in Morphic Holding, Inc. (NASDAQ:MORF) by 12.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 23,758 shares of the company’s stock after purchasing an additional 2,546 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Morphic were worth $686,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also made changes to their positions in the company. Wellington Management Group LLP raised its position in Morphic by 48.5% during the third quarter. Wellington Management Group LLP now owns 3,421,820 shares of the company’s stock valued at $78,394,000 after acquiring an additional 1,117,985 shares in the last quarter. Vanguard Group Inc. raised its position in Morphic by 10.5% during the third quarter. Vanguard Group Inc. now owns 2,107,410 shares of the company’s stock valued at $48,281,000 after acquiring an additional 200,772 shares in the last quarter. Federated Hermes Inc. raised its position in Morphic by 1.5% during the third quarter. Federated Hermes Inc. now owns 884,025 shares of the company’s stock valued at $20,253,000 after acquiring an additional 12,900 shares in the last quarter. Silverarc Capital Management LLC raised its position in Morphic by 134.2% during the third quarter. Silverarc Capital Management LLC now owns 590,829 shares of the company’s stock valued at $13,536,000 after acquiring an additional 338,520 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in Morphic by 14.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 304,276 shares of the company’s stock valued at $6,971,000 after acquiring an additional 37,264 shares in the last quarter. 94.25% of the stock is owned by hedge funds and other institutional investors.

Morphic Stock Performance

Shares of MORF opened at $27.69 on Thursday. Morphic Holding, Inc. has a twelve month low of $19.34 and a twelve month high of $63.08. The firm has a market cap of $1.39 billion, a PE ratio of -7.93 and a beta of 1.42. The firm’s 50 day moving average price is $33.55 and its 200 day moving average price is $29.01.

Morphic (NASDAQ:MORF) last released its quarterly earnings results on Thursday, February 22nd. The company reported ($0.94) EPS for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.05). On average, sell-side analysts anticipate that Morphic Holding, Inc. will post -3.9 earnings per share for the current fiscal year.

Morphic Profile

Morphic Holding, Inc, a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease.